Pharmacovigilance automation: the short answer
Pharmacovigilance automation means using software, rules and AI to handle the repetitive parts of drug safety work: capturing adverse event reports from email, call centres and portals, extracting the data, checking for duplicates, coding terms, drafting narratives and building submission files. It saves the most time at case intake and data entry, where reports arrive in dozens of formats. It should not replace the medical judgment on seriousness, expectedness and causality, which stays with qualified safety staff.
For a mid-sized pharma or biotech company, the practical goal is rarely a new safety database. It is getting every adverse event that reaches the company, from any channel, into the safety system complete, on time and with an audit trail, without adding headcount every time a brand grows. That job got more pressing in 2026. FDA's adverse event system, renamed from FAERS to the Adverse Event Monitoring System (AEMS), now requires the ICH E2B(R3) format for electronic postmarketing case reports from 1 October 2026, and the CIOMS Working Group XIV report on AI in pharmacovigilance, published in December 2025, gave the industry its first shared set of principles for using AI in safety work.
This guide covers which pharmacovigilance tasks to automate and how, the rules that apply, a worked example, costs, the commercial-channel blind spot most mid-sized companies miss, and the cases where you should not automate at all.
The numbers that set the deadline pressure
What pharmacovigilance automation covers, step by step
Intake
Reports arrive as emails, call centre notes, web forms, faxes, literature hits and partner files. Automation watches each channel, logs the receipt date (the clock start for the 15-day rule) and pulls the source into one queue, so nothing waits in an inbox.
Extraction
AI document processing reads the source and proposes the four minimum criteria for a valid case (an identifiable patient, an identifiable reporter, a suspect product and an adverse event) plus dates, doses and outcomes. A person confirms or corrects each field.
Triage
Rules check whether the case already exists, whether it meets the minimum criteria and whether keywords suggest seriousness, so possible 15-day cases rise to the top of the queue instead of sitting in date order.
Coding and narrative
Software suggests MedDRA terms for events and dictionary codes for products, and AI drafts the case narrative from the confirmed fields. The safety physician or case processor approves both. Coding suggestions are where tools save time; narratives need careful review.
Submission
Your safety database generates the E2B(R3) XML and sends it through ESG NextGen. Automation around it tracks due dates, acknowledgements and rejections, and alerts the team before a deadline is missed.
Reconciliation
Regular reconciliation compares adverse events logged by call centres, hubs, specialty pharmacies and vendors against cases in the safety database. Where it still runs in spreadsheets, it is one of the easiest steps to automate well.
Which PV tasks to automate, and how far
Decide task by task, not for the whole process. The table below reflects the human oversight models in the CIOMS XIV report: human-in-the-loop, where a person makes the final decision, and human-on-the-loop, where automation acts and a person monitors.
| Task | Best tool | Human role | Risk if wrong |
|---|---|---|---|
| Logging receipt date and source | Workflow automation | Spot check | Low, and easy to test |
| Reading emails, forms and PDFs into fields | AI extraction with confidence scores | Confirm every field on serious cases; sample on the rest once accuracy is proven | Medium: a missed event or wrong date |
| Duplicate detection | Rules plus fuzzy matching | Decide on possible duplicates | Medium: double counting or a merged case |
| MedDRA and product coding | Suggestion engine | Approve every code | Medium: wrong term affects signal work |
| Seriousness, expectedness, causality | None. Keep human | Decide | High: drives reporting timelines and labels |
| Narrative drafting | Generative AI from confirmed fields only | Edit and approve | Medium to high: invented detail |
| Due-date tracking and reminders | Workflow automation | Act on alerts | Low |
| Literature screening | AI relevance ranking | Review all hits above a set threshold, sample below it | Medium: a missed article |
| Reconciliation across sources | Data pipeline and matching rules | Resolve unmatched items | Low to automate, high to skip |
A rule of thumb: automate where the output is a fact you can check against the source document, assist where the output is a draft a qualified person edits, and keep human every decision that changes what gets reported and when. The same split applies in other regulated AI work, such as AI in MLR review, and our guide to RPA vs AI agents explains when a rule-based bot beats an AI model for steps like these.
The rules that apply to AI in pharmacovigilance
Reporting timelines do not change because software is involved. Under 21 CFR 314.80, serious and unexpected postmarketing adverse experiences must be reported as soon as possible and no later than 15 calendar days from initial receipt, follow-up information within 15 calendar days of receipt, and periodic reports quarterly for three years after approval (due within 30 days of quarter end) and annually after that (due within 60 days of the approval anniversary). The clock starts when anyone in the company receives the information, which is why intake automation pays for itself first.
The 2026 format change. FDA's AEMS page states that from 1 October 2026 all ICSRs submitted through ESG NextGen must use E2B(R3), and that IND safety reports from commercial sponsors moved to mandatory electronic submission on 1 April 2026. If your safety database or outsourced provider is already sending E2B(R3), the gateway is solved; the remaining work is data quality, because R3 carries more structured fields and rejects more incomplete cases.
FDA's view of AI. In January 2025 FDA published draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. It proposes a risk-based credibility assessment for AI models used to produce information supporting decisions on safety, effectiveness or quality, including in the postmarketing phase, and it judges model risk by two factors: how much the model influences the decision and how serious the consequences of a wrong decision are. A model that only drafts a field a person confirms has low influence; a model that decides whether a case is serious would have high influence and high consequence.
CIOMS XIV. The CIOMS report sets out seven principles: a risk-based approach, human oversight, validity and robustness, transparency, data privacy, fairness and equity, and governance and accountability. It deliberately avoids naming tools, and stresses representative testing and monitoring of performance, including on rare events, which matter more in safety than almost anywhere else.
Validation and records. Systems that create or change safety records sit inside your GxP and 21 CFR Part 11 controls: validated to a level proportionate to risk, with time-stamped audit trails. In practice that means every AI suggestion, the person who accepted or changed it, and the final value are all logged.
The blind spot: adverse events in commercial channels
Most pharmacovigilance automation content assumes reports arrive at the safety team. In mid-sized and specialty pharma, many first land somewhere else: a hub case manager's notes, a nurse educator call in a patient support program, a specialty pharmacy refill call, a field rep's conversation, a copay vendor's inbox or a market research interview. Each of those channels must pass adverse events to safety within agreed timelines, and each usually has its own system and its own spreadsheet.
FDA has made this visible in its own data model. Its AEMS submission page lists new study type values for Patient Support Program, Market Research Program and organised data collection from digital platforms, so reports from those sources can be labelled as such.
This is where automation built by a team that knows commercial data earns its keep. The work is not inside the safety database; it is around it:
- Scanning free-text notes in hub, PSP and call centre systems for possible adverse events, and routing hits to safety with the receipt date preserved.
- Matching every adverse event a vendor logs against the safety database, by patient token, date and product, and listing the gaps each month.
- Tracking each vendor's transfer time against the timeline in its safety data exchange agreement.
- Giving the head of safety one dashboard showing volume, timeliness and reconciliation status by channel.
If you already run patient services analytics, much of the plumbing exists. Our articles on AI tools for patient support programs and the patient services data blind spot describe the same data flows from the commercial side, and they connect to our wider specialty pharmacy analytics work.
A worked example: automating intake for a growing specialty brand
The figures below are illustrative assumptions chosen to show the arithmetic, not benchmarks. Replace them with your own volumes.
Take a specialty brand receiving 600 possible adverse event reports a month: half from its hub and patient support program, a quarter from the medical information line, and the rest from email, field teams and partners. Suppose a case processor spends 30 minutes per report today on finding the source, retyping it, checking for duplicates and chasing missing details. That is 300 hours a month of intake work.
- Capture and logging. A workflow pulls every report into one queue with the receipt date stamped. Assume this removes 5 minutes of searching and logging per report.
- Extraction. AI proposes the case fields with confidence scores. If confirming the fields takes 10 minutes instead of 20 minutes of typing, that saves another 10 minutes.
- Duplicate check and missing information. Rules flag likely duplicates and draft follow-up questions. Assume 5 minutes saved.
On those assumptions, intake time falls from 30 to 10 minutes per report, or from 300 to 100 hours a month, freeing about 200 hours for case assessment, follow-up and signal work. Seriousness, causality and coding approval are untouched; they remain with qualified staff. The number to test in a pilot is not the time saved but the miss rate: run the extraction on several hundred historical cases and measure how many events, dates or products it got wrong before anyone relies on it live.
How a pharmacovigilance automation project runs
Map every intake channel
List each place an adverse event can first appear, who owns it, the system it lives in and the agreed transfer time to safety. Look hardest for channels that nobody reconciles today.
Measure today's baseline
Record volume by channel, minutes per case at intake, late cases and reconciliation gaps for the last few months, so the benefit can be proven later.
Pick one low-risk, high-volume step
Usually receipt logging plus field extraction for one channel. Avoid anything that touches seriousness or causality in the first phase.
Test on historical cases
Run the automation on de-identified or synthetic copies of past cases and compare its output with what the team recorded. Set acceptance thresholds before you look at results.
Validate and update SOPs
Document intended use, risk assessment, test evidence and the human review step, and change the SOPs so auditors see the process that actually runs.
Go live with full review, then sample
Start with a person checking every output. Reduce review only where measured accuracy supports it, and keep monitoring performance by channel and product.
Common mistakes in PV automation projects
Letting AI decide seriousness
Seriousness and expectedness drive the 15-day clock. A wrong call either misses a deadline or floods FDA with unnecessary expedited reports. Keep both human.
Starting the clock late
The receipt date is when the company first knew, not when safety opened the email. Automation must capture the earliest date in the source channel.
Testing on live patient data first
Build and test on de-identified or synthetic cases, and run production on HIPAA-eligible services under your Business Associate Agreement where PHI is involved.
Automating only inside the safety database
The biggest leaks are upstream, in hubs, PSPs and vendors. A faster database does not help a case that never reached it.
No accuracy target before launch
Without a test set and an agreed miss rate, nobody can say when review can be reduced, and auditors will ask.
Buying a platform before fixing data
Mismatched product names, missing patient identifiers and free-text dates break every tool. Standardise the master data first.
What pharmacovigilance automation costs, and when not to buy it
Safety database vendors and PV service providers do not publish list prices, so treat any single number online with caution. What drives cost is predictable:
- Number of intake channels and how structured each one is. A web form is cheap to automate; scanned faxes and free-text call notes are not.
- Validation effort, which scales with risk. Receipt logging needs light validation; anything that proposes case data needs documented testing and change control.
- Integration with the safety database or your outsourced provider's system, and whether it accepts structured input.
- Ongoing monitoring: someone has to review accuracy reports and retest when models, products or forms change.
Published efficiency claims come from enterprise programmes. A PharmExec article by Cognizant authors cites 40 to 60 percent lower drug safety costs from automation in their client work; treat that as a vendor figure for large case volumes, not a forecast for a company handling a few hundred cases a month.
When not to automate. If you receive a few dozen cases a month and a PV provider already processes them under contract, building your own intake automation rarely pays back; spend the effort on making sure every commercial channel transfers events to that provider on time. Do not automate a process that is about to change, such as during a safety database migration or a vendor switch. And do not put AI near seriousness, expectedness or causality assessment until you have years of measured performance, if ever.
Where it does pay, the work is usually a mix of workflow automation, document AI and data matching rather than one product. Our AI workflow automation service builds exactly that layer around existing safety systems, and our AI agent development team handles the drafting steps that need guardrails and human approval.
Questions about pharmacovigilance automation
What is pharmacovigilance automation?
Can AI be used in pharmacovigilance?
Which pharmacovigilance processes can be automated?
What changed with E2B(R3) in 2026?
Do adverse events from patient support programs have to be reported?
Is automated adverse event processing compliant with FDA rules?
Should a small biotech automate PV or outsource it?
Want to know where adverse events slip through in your process?
Tell us which channels receive adverse events today and which systems they live in. We will map the flow in a short digital audit and show which steps to automate, which to leave with your safety team, and how to prove nothing is lost. Please do not send any patient or case information.
Part of our KPI Dashboards and BI hub. Start with our KPI dashboard development.